Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Demelo-Rodríguez

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Journal of Clinical Medicine|October 14, 2022
Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled TrialNuria Muñoz-Rivas, Jesús Aibar, Cristina Gabara-Xancó, et al.
Scientific Reports|March 5, 2025
Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 RegistryCrhistian-Mario Oblitas, Pablo Demelo-Rodríguez, Lucía Barrera-López, et al.
Viruses|March 28, 2024
Prognostic Value of D-dimer to Lymphocyte Ratio (DLR) in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Validation Study in a National CohortCrhistian-Mario Oblitas, Pablo Demelo-Rodríguez, Luis-Antonio Alvarez-Sala-Walther, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Journal of Clinical Medicine|October 14, 2022
Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled TrialNuria Muñoz-Rivas, Jesús Aibar, Cristina Gabara-Xancó, et al.
Scientific Reports|March 5, 2025
Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 RegistryCrhistian-Mario Oblitas, Pablo Demelo-Rodríguez, Lucía Barrera-López, et al.
Viruses|March 28, 2024
Prognostic Value of D-dimer to Lymphocyte Ratio (DLR) in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Validation Study in a National CohortCrhistian-Mario Oblitas, Pablo Demelo-Rodríguez, Luis-Antonio Alvarez-Sala-Walther, et al.
Pageof 8